Oxford Biomedica transforms into a pure-play CDMO in cell and gene therapy
LONDON, UK: Oxford Biomedica, a leading cell and gene therapy CDMO, has announced a business update for the year ending 31 December 2023. The update highlights the Company’s progress in transforming its operations, expanding its client base, and enhancing its capabilities across multiple viral vector platforms and sites. The Company has completed the reorganisation of…